GSK invests $110M in Relation Therapeutics to generate biological data for AI drug discovery

GSK announced an expanded collaboration with Relation Therapeutics in an investment of up to $110 million, where Relation will generate large-scale biological data to train AI models in drug discovery.

High-quality biological data is the foundation for training accurate AI models, helping understand cellular responses to genetic changes and drugs, thereby reducing failed trials and accelerating the path to new treatments.

The deal demonstrates the importance of investing in big data and AI in the healthcare sector, encouraging research institutions and startups in the region to adopt similar models to boost pharmaceutical innovation.

Key challenges include the lack of high-quality biological data, difficulty integrating data from multiple sources, the need for rigorous clinical validation, and high trial costs.